Experimental immune cell therapy takes on Hard-to-Treat myeloma
NCT ID NCT07458659
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a personalized cell therapy called CART-BCMA in 3 Thai patients with multiple myeloma that has returned or stopped responding to at least three prior treatments. The therapy uses the patient's own immune cells, modified in a lab to target and kill myeloma cells. The main goal is to check safety and find the right dose, while also looking for signs that the cancer shrinks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CART-BCMA (a CAR T-cell therapy made from the patient's own immune cells, engineered to target BCMA on myeloma cells)
- What this could lead to
- If it works, this could point toward a new treatment option for multiple myeloma that has stopped responding to other therapies.
- What could go wrong
- This is a very early, tiny trial (only 3 participants) focused on safety, not proof of effectiveness. The therapy may cause serious side effects or fail to control the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
King Chulalongkorn Memorial Hospital
Bangkok, Pathumwan, 10330, Thailand
More trials for these conditions
Other studies related to the condition(s) this trial covers.